Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

Bibliographic Details
Main Authors:	Maymona G. Abdelmagid, Mark R. Litzow, Kristen B. McCullough, Naseema Gangat, Animesh Pardanani, Hemant S. Murthy, James M. Foran, Rhett P. Ketterling, David Viswanatha, Kebede H. Begna, Ayalew Tefferi
Format:	Article
Language:	English
Published:	Nature Publishing Group 2022-07-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-022-00696-4

Similar Items

Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2023-03-01)

Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
by: Ayalew Tefferi, et al.
Published: (2024-03-01)

Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
by: Naseema Gangat, et al.
Published: (2023-01-01)

Targeted deep sequencing in primary myelofibrosis
by: Ayalew Tefferi, et al.
Published: (2016-12-01)

One thousand patients with essential thrombocythemia: the Mayo Clinic experience
by: Naseema Gangat, et al.
Published: (2024-01-01)

Detection of p190BCR-ABL AND p210BCR-ABL fusion transcripts in patients with chronic myeloid leukemia (CML) using qualitative RT-PCR
by: Aya Bonilla, Carlos Alberto, et al.
Published: (2014-10-01)

Prognostic impact of <i>SF3B1</i> mutation and multilineage dysplasia in myelodysplastic syndromes with ring sideroblasts: a Mayo Clinic study of 170 informative cases
by: Faiqa Farrukh, et al.
Published: (2024-03-01)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
by: Maymona G. Abdelmagid, et al.
Published: (2023-02-01)

Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2022-06-01)

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms
by: Terra L. Lasho, et al.
Published: (2018-02-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
by: Rimal Ilyas, et al.
Published: (2023-02-01)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
by: Ayalew Tefferi, et al.
Published: (2022-06-01)

Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
by: Naseema Gangat, et al.
Published: (2023-08-01)

Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels
by: Ayalew Tefferi, et al.
Published: (2018-08-01)

Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation
by: Mrinal M. Patnaik, et al.
Published: (2019-06-01)

Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis
by: Animesh Pardanani, et al.
Published: (2011-01-01)

Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval
by: Ayalew Tefferi, et al.
Published: (2024-03-01)

Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy
by: Naseema Gangat, et al.
Published: (2023-03-01)

Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
by: Ayalew Tefferi, et al.
Published: (2022-09-01)

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
by: Ayalew Tefferi, et al.
Published: (2023-07-01)

Molecular predictors of response and survival in patients with relapsed/refractory acute myeloid leukemia following venetoclax plus hypomethylating agent therapy
by: Isla M. Johnson, et al.
Published: (2025-02-01)

Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
by: Mostafa Abdallah, et al.
Published: (2023-03-01)

Papel da P190 BCR-ABL como parâmetro de recaída na leucemia mielóide crônica P190 BCR-ABL role in myeloid chronic leukemia relapse
by: Gabriela V. Andrade
Published: (2008-08-01)

How we diagnose and treat WHO-defined systemic mastocytosis in adults
by: Ayalew Tefferi, et al.
Published: (2008-01-01)

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases
by: Saubia Fathima, et al.
Published: (2025-03-01)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blastphase myeloproliferative neoplasm
by: Naseema Gangat, et al.
Published: (2022-12-01)

Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
by: Groffen John, et al.
Published: (2007-10-01)

<i>SF3B1</i>-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
by: Abhishek A. Mangaonkar, et al.
Published: (2022-02-01)

Emergence of <i>TP53</i> mutation during lenalidomide therapy of myelodysplastic syndrome with del(5q) and its subsequent disappearance following salvage therapy with decitabine
by: Naseema Gangat, et al.
Published: (2023-11-01)

Treatment-emergent mutations in myelodysplastic syndrome with del(5q) – lenalidomide related or disease-intrinsic clonal evolution?
by: Mostafa Abdallah, et al.
Published: (2024-03-01)

Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent
by: Nickolas Steinauer, et al.
Published: (2024-03-01)

Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms
by: Tariq I. Mughal, et al.
Published: (2014-05-01)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
by: Camille C.B. Kockerols, et al.
Published: (2020-12-01)

PREVALÊNCIA DA FUSÃO BCR-ABL1 P190 EM AMOSTRAS LABORATORIAIS
by: PV Macedo, et al.
Published: (2024-10-01)

Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience
by: Naseema Gangat, et al.
Published: (2022-02-01)

Quantification of Main Bcr-abl Gene Transcripts in CML Patients Using Competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Quantification of main bcr-abl gene transcripts in CML patients using competitive RT-PCR
by: Ali Nazemi, et al.
Published: (2016-04-01)

Distinct pattern of genomic breakpoints in CML and BCR::ABL1-positive ALL: analysis of 971 patients
by: Lenka Hovorkova, et al.
Published: (2024-07-01)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020-03-01)